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Abstract:  Nausea and vomiting of pregnancy (NVP) is a common medical condition in 
pregnancy with significant physical and psychological morbidity. Up to 90% of women will 
suffer from NVP symptoms in the first trimester of pregnancy with up to 2% developing 
hyperemesis gravidarum which is NVP at its worst, leading to hospitalization and even death 
in extreme cases. Optimal management of NVP begins with nonpharmacological approaches, 
use of ginger, acupressure, vitamin B6, and dietary adjustments. The positive impact of these 
noninvasive, inexpensive and safe methods has been demonstrated. Pharmacological treatments 
are available with varying effectiveness; however, the only drug marketed specifically for the 
treatment of NVP in pregnancy is Diclectin® (vitamin B6 and doxylamine). In addition, the 
Motherisk algorithm provides a guideline for use of safe and effective drugs for the treatment 
of NVP. Optimal medical management of symptoms will ensure the mental and physical 
wellbeing of expecting mothers and their developing babies during this often stressful and 
difficult time period. Dismissing NVP as an inconsequential part of pregnancy can have serious 
ramifications for both mother and baby.
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Introduction
Nausea and vomiting of pregnancy (NVP) is a debilitating condition affecting many 
pregnant women. Up to 90% of pregnant women will experience NVP of varying 
severity, with symptoms generally starting around 4–9 weeks of gestation, peaking 
around the 7th to 12th week, and subsiding by the 16th week.1–3 NVP symptoms will 
appear prior to ten weeks of gestation;1 women who experience NVP symptoms for 
the first time after 10 weeks, may be experiencing nausea and vomiting due to other 
medical conditions.4 The diagnosis of NVP is clinical in nature, and although other causes 
of persistent nausea, retching and/or vomiting are rarely encountered, failure to distinguish 
them from NVP can result in serious complications.5 Table 1 summarizes the differential 
diagnosis of patients with suspected NVP.
About 20%–30% of pregnant women will experience symptoms beyond 20 weeks, 
up to time of delivery.1,6,7 Less than 2% of women with NVP symptoms will develop 
hyperemesis gravidarum (HG), characterized by protracted vomiting leading to fluid 
and electrolyte imbalance, nutrition deficiency and a weight loss of more than 5% of 
the pre-pregnancy weight, often leading to hospitalization.8 Approximately 10% of HG 
patients will have persisting symptoms throughout pregnancy.1 To reduce   symptoms and 
subsequent suffering, as soon as NVP commences, women and their health care   providers 
should intervene with the appropriate treatment to prevent HG from occurring.9International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Generally it has been observed that women who 
  experience NVP have better pregnancy outcomes than those 
who don’t, and women who use antiemetics appear to have 
better pregnancy outcomes than women with NVP who don’t 
receive treatment.10 One explanation for this is that women 
who use antiemetics, tend to experience severe NVP which 
may be associated with a more robust placenta secreting 
high levels of hCG hormones; thus the better outcome for 
the antiemetic group of women could be attributed to the 
placenta itself and not so much the therapy.10
Despite many theories, the etiology of NVP remains 
unknown. Hormonal, immunological, anatomical and even 
psychological contributors to NVP and HG have been 
  proposed, although inconsistently, in many studies. Results 
to date remain inconclusive,8,9 as the cause is most likely 
multifactorial. Certain risk factors for experiencing NVP 
that have been proposed include decreased maternal age, 
increased placental mass, genetic predisposition, previous 
history of HG, multipara, fetal gender, and helicobacter 
pylori infection.9,11,12 A recent study examined potential risk 
factors regarding timing of onset, severity, and duration of 
NVP symptoms in more than 2000 women. It was reported 
that the duration of NVP is reduced in older women as well 
as non-Hispanic black and Hispanic women, and is increased 
with higher gravidity; however, severity of NVP was not 
associated with any of the aforementioned risk factors.13
NVP, especially HG, can be quite traumatic, both physically 
and mentally.14–16 In the absence of vomiting and retching, 
nausea alone can still have a detrimental effect on women’s 
wellbeing.14,17 Negative maternal consequences have been 
reported even postpartum; these include longer recovery time 
from pregnancy and persistence of symptoms post   delivery 
with greater intensity for women who had extreme weight 
loss.18 These symptoms include postpartum gallbladder dys-
function, food aversions, muscle pain, nausea, and symptoms 
characteristic of post traumatic stress disorder (PTSD).18
In addition to maternal consequences, negative impact of 
NVP on the fetus, family relationships, and job performance 
has also been documented.12,19 The most common adverse fetal 
outcome with severe vomiting is low birth weight and preterm 
birth; the more severe the nausea and vomiting, the lower the 
birth weight.9,12 Women report that their impairment due to 
nausea and vomiting compromises their parenting ability, as 
well as job performance, and very often family relationships are 
strained as a result of this distress.14 Moreover, the significant 
psychosocial morbidity caused by severe symptoms has resulted 
in elective pregnancy terminations, because women feel they 
cannot continue a pregnancy under these circumstances.9,14,20
A number of nonpharmacological and pharmacotherapy 
approaches have been proposed, investigated and recom-
mended for the treatment of NVP. We will address the safety 
and effectiveness of each treatment in this review.
Nonpharmacological approaches
Lifestyle
Many women experience a heightened sense of smell and 
metallic taste that appears to aggravate NVP symptoms 
resulting in aversions to different types of food that they 
otherwise regularly eat and enjoy. It has been hypothesized 
that this new aversion to certain types of foods, especially 
strong tasting vegetables and, in particular, meats and poultry, 
is a protective mechanism of NVP, by causing the mother to 
avoid potentially toxic or bacteria-containing foods.21
The Motherisk NVP line at Toronto’s Hospital for Sick 
Children has been counseling women on the management 
of NVP for more than 15 years. We have developed the 
following dietary guidelines, which have been followed by 
many clinicians.
 i.  Maintain adequate hydration and electrolyte levels; drink-
ing at least 2 liters of water a day.2
ii.  Avoid an empty stomach at all times, with small   frequent 
meals every 1–2 hours, consisting of bland foods through-
out the day.2,9,19
Table 1 Differential diagnosis of NvP
Gastrointestinal Genitourinary tract
• Gastroenteritis 
• Gastroparesis 
• Achalasia 
• Biliary tract disease 
• Hepatitis 
• Intestinal obstruction 
• Peptic ulcer disease 
• Helicobacter pylori 
• Pancreatitis 
• Appendicitis
• Pyelonephritis 
• Uremia 
• Ovarian torsion 
• Kidney stones 
•   Degenerating uterine  
leiomyoma
Metabolic Neurologic disorders
• Diabetic ketoacidosis 
• Porphyria 
• Addison’s disease 
• Hyperthyroidism/hypothyroidism
• Pseudotumor cerebri 
• vestibular lesions 
• Migraine headaches 
•   Tumors of the central 
nervous system
Miscellaneous Pregnancy-related 
condition
• Drug toxicity or intolerance 
 
• Psychologic and psychiatric disorders 
• Infections
•   Acute fatty liver of 
pregnancy
• PreeclampsiaInternational Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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  iii. Prevent a full stomach (ie, not mixing solids with liquid; 
avoiding large meals and very fatty food).2
  iv. Avoid strong tasting, odorous foods (ie, spicy, metallic 
tastes).2,9,19
  v. Snack on nuts and high protein foods between meals.22
  vi. Discontinue iron-containing prenatal multivitamins in 
early pregnancy,2,9 and switch to children’s chewable 
tablets and folic acid instead. Resume iron-containing 
prenatal vitamins after 12 weeks when iron is most 
needed by mother and baby. Pregnant women with 
past or current anemia should not discontinue prenatal 
vitamins, but may take them in divided doses.
 vii. Consume ice chips, popsicles, and very cold beverages 
to help reduce metallic taste.
viii.   Eat simple dry carbohydrates (ie, crackers, biscuits, etc) 
prior to getting out of bed in the morning.
Implementing uniform dietary changes can be quite 
challenging; consequently randomized controlled trials to 
investigate the effectiveness of dietary changes are lacking. 
Surveys conducted with women with NVP, especially 
HG patients, do report moderate relief with these dietary 
changes.23–25 One recent study also reported that women 
who have higher protein portions in their diet experience 
less severe NVP.22,26
Other recommendations include shortening food 
preparation time, allowing food to digest before lying down, 
eating more of the foods that are appealing, eating in a place 
that is comfortable, avoiding warm odorous places, drinking 
half an hour before or after but not during meals, drinking a 
cup of herbal tea with honey (eg, peppermint or chamomile) 
and wearing comfortable clothes.27 It has also been shown 
that brushing teeth after a meal, drinking peppermint tea, or 
sucking on peppermint candy, can ameliorate postprandial 
nausea.27
In addition to a healthy non-NVP provoking diet, it is also 
important to receive adequate amounts of sleep, as fatigue can 
aggravate NVP symptoms.19 This includes 8 hours of sleep 
at night, and taking time off work to rest when   experiencing 
NVP.
Acupressure
Acupressure is a complementary medicine technique closely 
related to acupuncture, consisting of certain pressure points 
in the body, where pressure is applied by finger, hand, 
elbow, or stimulated by electric devices. Pericardium 6 (P6) 
also known as point Neiguan, is an acupoint located about 
three fingers or 4.5 cm above the wrist on the inside of the 
forearm.28 According to Chinese medicine, P6 is considered 
the key point in relieving nausea and vomiting symptoms. 
Applying direct pressure or wearing wrist bands (ie, Sea 
Bands) may also alleviate symptoms. Several studies looking 
at the efficacy of wrist bands and electrical stimulation of P6 
have documented conflicting results; although most do report 
some initial relief, up to 50%, when compared with control 
groups.9,19,28 Although relief of symptoms has been associated 
with a placebo effect, a recent study with placebo and control 
groups did find a greater degree of relief in the treatment 
group; although the difference was not significant.9,28 Despite 
weak evidence of efficacy, acupressure is a safe, inexpensive, 
and noninvasive way to help reduce symptoms of nausea for 
some women and can be considered as a first option when 
trying to manage NVP symptoms.
Ginger
Ginger (Zingiber officinale), primarily grown in Asia and 
tropical areas, belongs to the family of plants that include 
cardamom and turmeric.29 The rhizome, the edible part of the 
ginger (often incorrectly referred to as the ginger root), has 
been used since ancient times for the treatment of a variety of 
medical conditions. A number of recently conducted studies 
have focused on the antiemetic effect of ginger, including 
treatment of NVP.29 Four of six randomized controlled trial 
studies prior to 2005 demonstrated the effectiveness of ginger 
in treating pregnancy-induced nausea and vomiting, with 
results that were superior to placebo. Two reported effective-
ness comparable to vitamin B6, which has also proven to be 
effective in treating nausea and vomiting of pregnancy.29
There are multiple preparations of ginger; either in the 
form of spice in foods and drinks, or extracts in teas and cap-
sules.19 Randomized controlled trial studies have used d  ifferent 
formulations of root powder, capsule, or extract in dosages of 
250 mg up to 1000 mg/day (root powder   equivalent); and it 
has been shown that there is a significant reduction in the num-
ber of episodes of   vomiting as well as severity and duration 
of nausea in women on this regimen.9,29,30 One recent study 
reported that ginger is   superior to vitamin B6 in decreasing the 
severity of nausea.31 In addition, a 1000 mg/day dosage was 
effective without any negative pregnancy outcomes, so dos-
ages of 1000 mg or lower per day can be used without safety 
concerns. Adverse impacts may include mild gastrointestinal 
effects such as heartburn, diarrhea, and mouth irritation, but 
these are generally uncommon.29
In summary, it appears that ginger is a safe, effective, 
and inexpensive solution for treating NVP and should be International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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considered as a first-line option for management of NVP 
symptoms, or as adjuvant with other forms of therapy.
Pharmacological approaches
Pyridoxine/vitamin B6
B6 is a water soluble vitamin that is an essential coenzyme 
for the metabolism of amino acids, lipids, and carbohydrates. 
Pyridoxine or vitamin B6 has been studied extensively for 
its antiemetic property. Two randomized controlled studies 
reported that vitamin B6 significantly reduced the severity 
of NVP symptoms in women with moderate or severe 
nausea and vomiting, when compared with placebo.32,33 
Although no relationship has been found between B6 status 
and the incidence of morning sickness, using 10–40 mg/day 
appears to reduce the severity of NVP symptoms.32,33 Its 
effectiveness for reducing the severity of NVP has been 
used as a parameter in several studies to compare the effec-
tiveness of ginger in reducing NVP symptoms with ginger 
appearing superior to B6.30,34,35 The B6 dose can be adjusted 
according to maternal weight and severity of NVP, and 
maternal doses of up to 500 mg/day can be used without 
increasing maternal adverse effect or jeopardizing fetal 
safety.35 However, a dose of up to 200 mg/day, as suggested 
in the 2007 Motherisk NVP algorithm, is the current recom-
mended high dose. Concerns about maternal toxicity have 
been reported with dosages much higher than 500 mg/day, 
and in the 2000–6000 mg/day range.35
Doxylamine/pyridoxine combination
The delayed release formulation of doxylamine and 
pyridoxine combination, known as Bendectin® in the United 
States and Debendox® in the United Kingdom, was available 
and widely prescribed to pregnant women with NVP from 
1958–1983.9,19,36 In 1983 the manufacturer voluntarily 
removed the drug from the market due to litigations and 
false allegations regarding teratogenic effects. Consequently, 
there was a 2–3-fold increase in the rate of hospitalization 
due to NVP.9,35,36 Many case control and cohort studies, with 
over 170,000 exposures have demonstrated the safety of the 
combination of doxylamine and pyridoxine, and although 
it is no longer commercially available in the United States, 
many compounding pharmacies will prepare the combina-
tion on request.7 Women will also take a combination of 
doxylamine succinate (ie, Unisom®) and a vitamin B6 tablet 
for the same effect. In Canada, the combination is marketed 
as Diclectin®, and is considered the first line drug therapy 
for the treatment of NVP.35,36
Diclectin® contains 10 mg doxylamine succinate and 10 mg 
pyridoxine HCL in a delayed-release formulation; doxylamine 
is an antihistamine that blocks H1 receptors, and the safety of 
H1 antagonist antihistamines have been demonstrated in over 
200,000 first trimester exposures.35–37 The standard dose of 
Diclectin® is 4 tablets/day and is recommended to be taken as 
2 tablets at bedtime, 1 in the morning and 1 in the afternoon. 
The delayed-release formulation ensures the availability of the 
drug in the morning when it’s taken at night, in the afternoon 
when taken in the morning, and in the evening when taken in 
the afternoon.36 It may take several days to experience the full 
effect of the medication, and women should not discontinue 
therapy or be discouraged if they don’t find immediate relief. 
The standard dosage can be adjusted based on severity of 
NVP and maternal weight. The safety of higher doses of up to 
12 tablets per day has been demonstrated without increasing 
adverse effects, or fetal risk; side effects of tiredness, drowsi-
ness and sleepiness, as well as birth defects and birth weight, 
were not increased with supra doses of Diclectin®.35,36
As the only drug approved for use in pregnancy, Diclectin® 
should be used as first-line therapy for the treatment of NVP 
symptoms in women, as studies have shown a 70% decrease 
in nausea and vomiting with its use.9
Antihistamines
Other H1-blocker antihistamines such as dimenhydrinate 
(Gravol®) and diphenhydramine (Benadryl®), have been used 
for NVP treatment without safety concerns. Exposure of more 
than 200,000 first trimester women from 24 different studies, 
failed to show any increase in the baseline risk of 1%–3% 
for birth defects; in fact it was found that these women had 
a slightly lower risk for malformations.38 Pooled data from 
several different studies have documented the effectiveness 
of a variety of H1 blocker antagonists in reducing nausea 
and vomiting symptoms.38 Other H1 blocker antihistamines 
that have been used in pregnancy include buclyzine, 
cyclizine, hydroxyzine, and meclizine. The availability of 
some of these antihistamines (ie, cyclizine) in suppository 
or parenteral formulation, makes them appropriate choices 
for the treatment of acute or breakthrough NVP.36
Dopamine antagonists
Phenothiazines
Phenothiazines such as chlorpromazine, perphenazine, prochlo-
rperazine, promethazine, and trifluoperzaine, have shown to 
be superior to placebo in the treatment of severe NVP.36,38,39 
The aggregate of data has failed to find an increase for adverse International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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effects in babies whose mothers took   phenothiazines during 
pregnancy.38 Thus, they may be implemented in the regimen 
for management of NVP when other antiemetics are unavail-
able or have not been effective (Figure 1).
Metoclopramide
Metoclopramide is an upper gastrointestinal motility stimu-
lant and has been used in clinical practice for the treatment 
of NVP.36 In Canada, with the availability of Diclectin®, 
metoclopramide use is reserved for more severe cases of NVP. 
However, in some European countries and Israel it has been 
the drug of choice for treatment of NVP for decades, despite 
the lack of evidence for safety in pregnancy.40 In recent years, 
a few small studies conferred safety;36 however, the largest 
study to date was published in 2009, with more than 3400 1st 
trimester exposures and there was no increased risk for major 
malformations.40 Subcutaneous metoclopramide is effective 
in many women with NVP and HG.41 These findings are 
reassuring, especially for women who experience excessive 
sleepiness from the doxylamine in Diclectin®, which can be 
quite disruptive for some.40,41 Side effects with metoclopr-
amide therapy include akathesia and other extrapyramidal 
symptoms, which are generally quite minor, and dependent 
on dose and duration of treatment.38
Give 10 mg of doxylamine combined with10 mg of pyridoxine (Diclectin, delayed release) up
to 4 tablets daily (ie, 2 at bedtime, 1 in the morning, and 1 in the afternoon). Adjust schedule
and dose according to severity of symptoms.*
Add dimenhydrinate 50 to 100 mg every 4 to 6 h PO or PR up to 200 mg/d when
taking 4 Diclectin tablets daily (if vomiting frequently, take 30 to 45 min before
taking Diclectin); or promethazine 12.5 to 25 mg every 4 to 6 h PO or PR
NO DEHYDRATION DEHYDRATION
Add any of the following:
NOTE Add any of the following:
Add 1 of the following:
Start rehydration treatment:
(listed in alphabetical order)
(listed in alphabetical order)
•  chlorpromazine 10 to 25 mg every 4 to 6 h
    PO or IM or 50 to 100 mg every 6 to 8 h PR
•  metoclopramide 5 to 10 mg every 8 h IM or PO
•  use of this algorithm assumes that other causes of NVP have 
    been ruled out. At any step, when indicated, consider total 
    parenteral nutrition.
•  At any time you can add any or all of the following:
–  pyridoxine (vitamin B6) 25 to 50 mg every 8 h PO†
–  ginger root powder, capsules, or extract§
    up to 1000 mg/d, and
–  accupressure or acupuncture at acupoint P6
• multivitamin IV supplementation
• chlorpromazine 25 to 50 mg every 4 to 6 h IV
• metoclopramide 5 to 10 mg every 8 h IV
•  methylprednisolone 15 to 20 mg every 8 h IV
    or 1 mg/h continuously up to 24 hII
•  ondansetron 8 mg over 15 min every 12 h IV or 
    1 mg/h continuously up to 24 h 
• prochlorperazine 5 to 10 mg every 6 to 8 h IV
• promethazine 12.5 to 25 mg every 4 to 6 h IV
• dimenhydrinate 50 mg (in 50 mL of saline,
   over 20 min) every 4 to 6 h IV
•  ondansetron 4 to 8 mg every 6 to 8 h PO
• IV fluid replacement (per local protocol)†
•  prochlorperazine 5 to 10 mg every 6 to 8 h IM or PO
•  promethazine 12.5 to 25 mg every 4 to 6 h IM, PO, or PR
* Study showed that up to 8 tablets daily did not increase baseline risk for 
   major malformations or any other adverse effects.6 Monitor for potential 
   side effects of Diclectin and other H1 blockers.
†No study has compared various fluid replacements for NVP.
‡Safety of up to 200 mg/d of B6 has been confirmed.7
§Ginger products are not standardized.
IISteroids are not recommended during the first 10 wk of 
pregnancy because of possible increased risk for oral defts.
Figure1 Pharmacological treatment of nausea and vomiting of pregnancy: if no improvement, proceed to next step. 
Abbreviations: IM, intramuscular; Iv, intravenous; NvP, nausea and vomiting of pregnancy; PO, by mouth; PR, by rectum.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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5-HT3 antagonist
Ondansetron is effective in treating nausea and vomiting 
associated with chemotherapy, which lead to its increased 
use in treating nausea and vomiting of pregnancy.9 It is the 
most commonly used 5-HT3 antagonist for the treatment 
of severe NVP, usually when other types of therapy prove 
ineffective. A limited number of case series and one study 
from Motherisk which included 176 women exposed to 
ondansetron in the 1st trimester, failed to find an association 
between exposure in first trimester and increased risk for 
major malformations.38,42,43 Although it may help with reduc-
ing symptoms, IV ondansetron was not found to be more 
effective than promethazine.36,38 Because of cost and pau-
city of data regarding use in pregnancy, this drug should be 
reserved for when other forms of therapy prove ineffective.
Others
Anticholinergics
Dicyclomine and scopolamine have been used in the 
  nonpregnant population for the treatment of nausea and 
vomiting. Pregnancy exposures have not shown an increase 
in baseline risk for malformations with either drug.38 
  Effectiveness studies for scopolamine are lacking, and the 
existing evidence for dicylomine fail to show improvement 
in NVP symptoms.38 Using either drug for NVP is not 
recommended as a first choice; scopolamine, available as 
transdermal patches, is a good option if the patient has trouble 
swallowing tablets or dislikes using suppositories.
Corticosteroids (dexamethasone, 
methylprednisolone, etc)
Corticosteroids have successfully been used for the treatment 
of chemotherapy-induced nausea and vomiting. Their use 
in pregnancy, however, has been associated with a small but 
significant increase in the incidence of oral cleft in a study 
published by Motherisk.44 A number of reports have shown 
successful use for treatment of HG, although the pooled 
data failed to show superiority to placebo or promethazine 
in the treatment of NVP.38 Due to the small risk for oral cleft, 
the use of corticosteroids should be reserved for treatment 
when other drugs have been ineffective and only following 
10 weeks gestation as per the Motherisk NVP algorithm 
(Figure 1).
Acid reflux/heartburn pharmacotherapy
Gastrointestinal reflux disorders are common medical 
  conditions in pregnancy, with up to 85% of pregnant 
women experiencing some or all symptoms associated 
with dyspepsia, which include heartburn/acid reflux (HB/
RF), regurgitation, belching, flatulence, stomach   bloating, 
indigestion, and sensation of a lump in the back of the 
throat; over 50% have shown to experience HB/RF in first 
trimester.45 One recent prospective study demonstrated an 
increase in severity of NVP symptoms in the presence of 
HB and/or RF; it was also noted that women who experi-
ence both tend to classify their NVP as severe, compared 
with women who were experiencing just one or neither 
HB/RF.46 With exacerbation of NVP symptoms due to HB/
RF, the use of acid-reducing agents will provide relief for 
many women. Acid-reducing pharmacotherapy includes the 
use of antacids, H2-histamine blockers, and proton pump 
inhibitors, all of which have been studied quite extensively 
in pregnancy, with proven safety.46–48 The effective treat-
ment of HB/RF with these drugs has corresponded with 
a significant decrease in the severity of NVP symptoms 
experienced by women and a significant increase in well-
being.46 Thus the treatment of HB/RF symptoms with acid 
reducing agents, in conjunction with other antiemetics, 
should be encouraged as part of standard NVP manage-
ment. Prior to treatment of HB/RF symptoms, patients 
with severe NVP should be tested for the presence of 
helicobacter pylori infection, which has been associated 
with hyperemesis gravidarum and increased severity of 
gastrointestinal conditions.11,48
Rehydration/enteral or parenteral 
nutrition
When persistent weight loss and/or dehydration is present 
despite antiemetic therapy, as usually observed with HG 
patients, serious complications may arise if the patient is not 
treated. Intravenous rehydration must be used for women who 
cannot tolerate liquids or show clinical signs of dehydration; 
vitamins and electrolytes should be replenished, and ketosis 
should be corrected in these patients.9,36 When vomiting is 
prolonged, dextrose, vitamins, especially thiamine, should 
be included in the therapy.9
Women who continue to lose weight and cannot tolerate 
food, should be considered for enteral tube feeding first, prior 
to considering parenteral feeding, as this condition has been 
associated with life-threatening complications.49 A recent 
study involving refractory hyperemesis in a small group of 
women reported a clear reduction in the extent of vomiting 
and a complete cessation, 2–5 days respectively, after tube 
insertion; weight gain was observed in some women who 
stayed on tube feeding for more than 4 days.50International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
247
Optimal management of nausea and vomiting of pregnancy
Peripheral parenteral nutrition, using a central catheter 
inserted peripherally, containing high lipid formulation, is 
used in patients who do not require a high caloric intake 
and whose treatment length is short term.9,51 The use of total 
  parenteral nutrition (TPN) has been employed for women with 
life-threatening cases of HG with zero tolerance for any food 
intake, in order to provide adequate maternal nutrition and 
continued fetal growth. Due to the high risk associated with 
TPN – thrombosis, metabolic disturbances, and infectious 
complications – it should be used as a last resort, when all 
other modalities have failed.50 With carbohydrate rich TPN, 
thiamine supplementation as a prophylactic measure against 
Wernicke’s encephalopathy is extremely important.50
Conclusion
The physical and psychological morbidity associated with 
NVP is a major deterrent of wellbeing for many women, with 
marked negative impact on their pregnancy experience.52,53 
Fortunately, evidence-based information in the literature does 
exist, making the management of NVP medically possible. 
Prior to starting pharmacological therapy, women should 
try the appropriate dietary changes and incorporate the use 
of ginger and vitamin B6, which may eliminate the need for 
further intervention. If these treatments are not effective, 
pharmacotherapy should be started as all the drugs used in 
the treatment for NVP appear to be safe for the fetus and 
have some degree of effectiveness.
Treatment with pharmacotherapy should follow the 
stepwise guide in Figure 1; the treatments outlined are listed 
in alphabetical order and it is the physician’s decision to 
decide which order is most appropriate according to their 
patient’s condition. The use of antiemetics should begin with 
Diclectin® or any doxylamine/pyridoxine combination, as the 
largest body of evidence exists for their efficacy and safety. 
Other antiemetics can be implemented according to the 
algorithm if symptoms don’t resolve. Concurrent   treatment 
of HB and RF, using antacids, H2-blockers and proton 
pump inhibitors, is also encouraged.45,46 These techniques 
should only be implemented when other causes of nausea 
and vomiting have been ruled out (Table 1). Treatment of 
these underlying conditions can bring relief to women and 
eliminate the need for any further treatment.
Health care providers should recognize NPV as a 
medical condition with significant potential to compromise 
women’s wellbeing, even when symptoms are moderate, and 
should not hesitate to treat aggressively. Dismissing NVP 
as an inconsequential part of pregnancy, and not   providing 
  adequate treatment, can seriously compromise the health 
of both mother and fetus. The attitude and practices of 
physicians and other health care providers is integral in the 
management of this debilitating condition.54
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